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Abstract
Background: A major challenge in treating acute asthma exacerbations is the need to open constricted airways
rapidly enough to reestablish ventilation and allow delivery of conventional medication to diseased airways. The
solution requires a new approach that considers both biophysical and pharmacological aspects of treatments used
in acute asthma. The result of testing several formulations was S-1226: carbon dioxide-enriched air delivered
in nebulized perflubron, a synthetic surfactant. These agents act synergistically to rapidly reopen closed airways within
seconds. The bronchodilator effect is independent of β-adrenergic and cholinergic mediated-signaling pathways,
offering a unique mechanism of action. S-1226 has a low toxicity profile and was effective in treating bronchoconstriction
in animal models of asthma. The goal of the present study was to evaluate the safety and tolerability of S-1226 in
healthy human subjects.
Methods: The phase I study was a single-center, randomized, double-blind, placebo-controlled, sequential, single-
ascending-dose study conducted in Canada. Thirty-six subjects were distributed into three cohorts. Within each
cohort, subjects were randomized to receive a single dose of S-1226 or a matching placebo administered over
a 2-minute nebulization period. S-1226 was formulated with perflubron and 4 %, 8 %, or 12 % CO2. The dose of
CO2 was sequentially escalated by cohort. The safety and tolerability of S-1226 were evaluated through assessment of
adverse events, vital signs, 12-lead electrocardiograms, clinical laboratory parameters, and physical examinations.
Results: S-1226 was safe and well tolerated at all three CO2 levels (4 %, 8 %, and 12 %). A total of 28 adverse events
were reported, and all were judged mild in severity. Twenty-four adverse events occurred in the S-1226 cohort,
of which five were considered remotely related and six possibly related to S-1226.
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Conclusions: S-1226 is a novel drug being developed for the treatment of acute asthma exacerbations. It consists of
CO2-enriched air and perflubron and has potential to offer rapid and potent bronchodilation. The results of the study
indicate that S-1226 is safe and well tolerated. All adverse events were mild, reversible, and likely due to known side
effects of CO2 inhalation.
Trial registration: ClinicalTrials.gov NCT02616770. Registered on 25 November 2015.
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Background
According to the Global Asthma Report, the prevalence
of asthma is 334 million individuals worldwide, and this
number is projected to continue to rise [1]. Furthermore,
an estimated 250,000 people die prematurely as a result
of asthma each year. In most cases, these deaths are
avoidable and could be prevented [2]. In 2011, 8.6 % of
Canadians aged 12 years or older were reported to be di-
agnosed with asthma [3].
Healthcare costs of asthma are considered to be among
the highest associated with chronic disease. In Canada, it
is estimated that 65 % of patients with asthma treated in
general practice have poorly controlled disease [4]. Fur-
thermore, asthma is the leading cause of hospitalization,
with the cost of urgent care (including hospitalizations,
unscheduled physician and emergency department visits,
medications, and ambulance services) associated with the
disease being assessed at $46 million to $141 million per
annum [3, 5]. Inhaled short-acting β2-agonists (with or
without accompanying anticholinergic agents and sys-
temic corticosteroids) represent the most common
frontline emergency department treatment for acute
exacerbations because of their well-known rapid broncho-
dilatory effect [6, 7]. However, many patients do not re-
spond to these treatments, resulting in disproportionate
consumption of healthcare resources [8].
In an acute asthma exacerbation, bronchoconstric-
tion upon a background of mucous plugs, vascular
congestion, inflammation, and airway remodeling charac-
teristic of severe asthma can result in fatal hypoxemia.
Autopsy examination reveals lungs characterized by areas
of hyperinflation and collapse, as well as airways blocked
by large, tenacious mucous plugs [9]. Poor response
to initial therapy requires more aggressive strategies,
with approximately one-third of patients with asthma
admitted to intensive care units requiring intubation
and mechanical ventilation [7, 10]. The latter treat-
ment requires high pressure, resulting in barotrauma
and associated complications [10].
The major challenge in treating acute asthma exacer-
bations is the need to open constricted airways rapidly
enough to reestablish ventilation and allow delivery of
oxygen and conventional medication to the diseased
airways and to reduce the risk for barotrauma. It requires
a new approach, one that takes into account both the bio-
physical and pharmacological aspects of acute asthma.
Our investigations resulted in the development of S-
1226, an aerosol-vapor-gas mixture of CO2 and perflubron.
CO2 and perflubron work together synergistically via both
pharmacological and biophysical principles, offering a
unique mechanism of action to rapidly dilate airways.
Carbon dioxide
CO2 is an odorless, colorless, relatively inactive, non-
flammable gas found in trace amounts in the atmos-
phere (0.038 %). It plays multiple roles in homeostasis in
all living organisms and is essential for normal cellular
function [11]. When CO2 is inhaled, or after it is pro-
duced by cellular respiration, it is dissolved into the
blood, where it reacts with water. The carbonic enzyme
that is formed when CO2 undergoes hydration in the
bloodstream is used in renal function and in maintaining
a proper internal pH balance. CO2 acts through the
stimulation of chemoreceptors in the carotid bodies and
respiratory control centers in the brain and brainstem
[12] to increase breathing frequency and tidal volume
[13]. CO2 also has a direct, dose-dependent, relaxant ef-
fect on vascular and bronchial smooth muscle [12, 14, 15],
resulting in increased gas exchange and compliance within
the lungs [16].
Inhaled CO2 is a known bronchodilator for many
mammalian species [16]. In vitro studies have shown
that hypercapnia relaxes airway smooth muscle [17, 18],
whereas hypocapnia constricts it [19]. Similar effects are
seen in vivo: Hypocapnia causes bronchoconstriction in
healthy individuals and patients with asthma, whereas
hypercapnia reduces airway resistance [20]. A study of
young patients with atopic asthma demonstrated that
inhalation of 6 % CO2 over 4–5 minutes relieved exer-
cise-induced airflow obstruction, both at rest and during
exercise, with no significant side effects reported [13].
Perflubron
Perflubron is chemically an extremely stable, inert com-
pound [21]. It is one of the most widely used perfluoro-
carbons and has been used extensively in clinical
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applications, including bronchial lavage, liquid ventila-
tion, and gastrointestinal contrast-enhanced imaging,
with no significant toxicity, as it is not metabolized and
is minimally absorbed [21, 22]. It is hydrophobic and
slightly less lipophobic than most perfluorocarbons of
the same molecular weight, and it has among the great-
est O2 and CO2 solubilities relative to its molecular
weight [21, 23]. Perflubron also possesses high density
and low surface tension, making it compatible with en-
dogenous airway surfactant. It has mucolytic properties
in vitro [24]. In pulmonary applications, perflubron is
associated with improved lung compliance and gas ex-
change [25, 26]. In preclinical evaluations, aerosolized per-
flubron reduced pulmonary inflammation in addition to
improving lung compliance and gas exchange [27, 28].
Thus, perflubron acts as the biophysical component
of S-1226, and its effect is believed to be due to com-
patibility of perflubron with airway surfactant, its muco-
lytic properties, and its ability to absorb CO2. It may
reduce inflammation and irritation by suppressing airway
irritant receptors that cause bronchoconstriction.
S-1226
S-1226, the combination of CO2-enriched ambient air
delivered in nebulized perflubron, was shown to rapidly
open obstructed airways in a sheep model of chronic al-
lergic asthma with an effect that was greater and more
prolonged than that of either CO2 or perflubron alone
[29]. Moreover, studies using methacholine showed that
S-1226 dilated constricted ovine airways within seconds,
indicating a neural mechanism, potentially by activating
noncholinergic, nonadrenergic nerves located between
the epithelial cells in the bronchial mucosa [19].
The clinical indication for S-1226 is for the treatment
of acute asthma exacerbations. It would complement
existing rescue treatments for asthma, as it acts via a
different mechanism to β2-agonists such as salbutamol
or cholinergic antagonists [19]. Furthermore, the bio-
physical properties of S-1226 indicate that it will have
mucolytic properties, thus providing relief when conven-
tional therapies fail. If S-1226 is proven to be effective in
humans, it may be possible to develop a portable rescue
device similar to an EpiPen® (Mylan, Canonsburg, PA,
USA) for patients with asthma at risk for an acute exacer-
bation. S-1226 also has potential for treating other ob-
structive airway diseases, such as chronic obstructive
pulmonary disease and cystic fibrosis, and as a platform
technology to enhance delivery of other drugs to the lung.
Objective
In the present study, we sought to evaluate the safety and
tolerability of S-1226, composed of 3 ml of perflubron
with ascending doses of carbon dioxide (4 %, 8 %, and
12 % CO2) administered over a 2-minute nebulization
period to healthy subjects. This phase I study is reported
following the Consolidated Standards of Reporting Trials
(CONSORT) 2010 checklist (Additional file 1).
Methods
Trial design
We conducted a single-center, phase I, randomized,
double-blind, placebo-controlled, sequential, single-
ascending-dose study in Canada. The study included
three cohorts. Within each cohort, subjects were random-
ized to receive a single dose of S-1226 (nine subjects) or a
matching placebo (three subjects). The dose of CO2 in S-
1226 was sequentially escalated cohort by cohort from the
starting dose of 4 % CO2. Planned subsequent dose levels
were 8 % and 12 % CO2. Randomization within each co-
hort was imbalanced, with a study drug-to-placebo ratio
of 3:1. The study was designed to evaluate the safety and
tolerability of S-1226 in healthy male and female subjects
under fasting conditions, with a total of 36 subjects
equally distributed into three cohorts. Procedures com-
pleted during study screening, evaluation, and exit are de-
tailed in Table 1.
In each cohort, a sentinel group of two subjects was
dosed on day 1: one sentinel was dosed with the test
product (S-1226) and the other sentinel with the match-
ing placebo. The remaining subjects of the same cohort
were dosed at least 24 h after sentinel dosing with ap-
proval from the qualified investigator upon assessing the
sentinel group. Following dosing of each cohort, safety
and tolerability data were collected for at least 24 h post-
dose and evaluated by a safety monitoring committee.
The subjects also returned for a follow-up visit 5 days
(±1 day) after dosing. The safety monitoring committee,
composed of Dr. Richard Leigh, Dr. Francis Green, and
Dr. Xueyu (Eric) Chen, reviewed the results from each
cohort before making a decision regarding continuation
of the study at the next prescribed dose level, decreasing
the next dose level, repeating a dose level, or whether to
evaluate any additional dosage, based on consideration
of the clinical significance of safety and tolerability
parameters. There was at least a 7-day period be-
tween dosing at each dose level.
Participants
The study population included nonsmoking male and
female volunteers from 18 to 55 years of age with a body
mass index between 18.5 and 30.0 kg/m2 who were judged
to be healthy based on a medical history, electrocardio-
gram (ECG), laboratory evaluation, physical examination,
vital sign measurements, pulse oximetry, spirometry, radi-
ography, being capable of providing consent, and having
normal lung function (forced expiratory volume in 1 sec-
ond [FEV1] ≥ 80 % of predicted and FEV1, forced vital
capacity >70 %).
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Participants to whom any of the following applied
were excluded from the study:
1. Any clinically significant abnormality or abnormal
laboratory test results, including clinical ECG
abnormalities, vital sign abnormalities, or positive
test for hepatitis B, hepatitis C, or HIV found
during medical or laboratory screening
2. History of significant allergic reactions, panic
disorder or panic attacks, wheezing after exercise,
and previous medical diagnosis of asthma
3. Positive urine drug screen or urine cotinine test at
screening
4. Current cigarette smokers or former smokers with a
smoking history >5 pack-years or who had stopped
smoking within the 2 years preceding enrollment in
the study
5. History of significant alcohol abuse within 6 months
of the screening visit and/or a history of significant
drug abuse within 1 year prior to screening
6. Use of anticoagulants, immunosuppressives,
nonsteroidal anti-inflammatory drugs, anti-
Table 1 Study screening, evaluation, and exit procedures







visit day 5 ± 1)
Demographic data X
Medical and medication histories X
Review of AEs and concomitant medications X X
Physical examination X X X X
Height and weight X
Vital signs X X Xa* X
Tympanic temperature X X X
Spirometryb X Xc*
Chest x-ray X
ECG X Xd* X
Biochemistry X X Xe* X X
Hematology X X Xf* X X
HIV and hepatitis X
Urinalysis X X X X
Urine drug screen X X
Urine cotinine test X X
Alcohol breath test X X
Serum pregnancy test X X
Urine pregnancy test X
Confinement X X
Drug administration X
PK blood sample Xe* X
PK urine sample (for perflubron measurements) Xg* X
Pulse oximetry X X Xa*
Adverse event monitoring X X X X
AE adverse event, ECG electrocardiogram, PK pharmacokinetic
* For study procedures scheduled at the same time point, the order of precedence is as follows:
i. Blood draws (hematology and biochemistry)
ii. ECG
iii. Vital signs and pulse oximetry
iv. Spirometry
aBlood pressure, heart rate, respiratory rate, and pulse oximetry: predose and 20 minutes, 1 h, 2 h, 3 h, and 4 h postdose
bFor screening, spirometry was forced expiratory volume in 1 second (FEV1) and forced vital capacity; for confinement, spirometry was FEV1 only
cSpirometry within 1 h of drug administration (predose) and at 25 minutes, 1 h, 3 h, and 8 h (only if values before that are abnormal) after the end of study
drug administration
dECG predose and at 15 minutes, 1 h, 3 h, 4 h, and 8 h (only if values before that are abnormal) postdose
eBiochemistry and PK blood samples were collected predose and at 3 minutes, 30 minutes, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h postdose
fHematology was done predose and at 30 minutes, 2 h, 8 h, and 24 h postdose
gUrine samples were collected over the following time intervals: predose and 0–4 h, 4–8 h, 8–12 h, and 12–24 h postdose
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immunoglobulin E medication, or any allergen-specific
immunotherapy within the last 60 days and use
of medications other than nonsteroidal topical
products without significant systemic absorption,
such as prescription medication, over-the-counter
products including natural health products, a depot
injection or an implant of any drug, or monoamine
oxidase inhibitors
7. Hemoglobin level <128 g/L (males) and <115 g/L
(females) and hematocrit <0.37 L/L (males) and
<0.32 L/L (females) at screening
8. Donation of blood within 7 days prior to dosing or
blood loss ranging from 50 ml to >499 ml within
56 days prior to dosing
9. Breastfeeding subjects and participants with a positive
pregnancy test at screening
10. Any reason that, in the opinion of the investigator
(or delegate), would prevent the subject from
participating in the study
11. Use of an investigational drug within 30 days
(90 days for biologics) or participation in an
investigational study within 30 days prior to dosing
Locations where data were collected
The study took place at Pharma Medica Research Inc.
(PMRI) in Toronto, ON, Canada. The clinical laboratory
facility used was Alpha Laboratories Incorporated in
Toronto.
Interventions
S-1226 is formulated with 3 ml of perflubron and 4 %,
8 %, or 12 % CO2. Each formulation is inhaled directly
from a nebulizer over a 2-minute administration period.
Subjects received, under fasting conditions, a single dose
of S-1226 or matching placebo administered over
2 minutes with a Circulaire® II hybrid nebulizer sys-
tem (Westmed, Tucson, AZ, USA) at a flow rate of
8.9 L/minute. The nebulizer was filled with either
3 ml of perflubron driven by a compressed medical gas
mixture containing CO2 (S-1226) or 3 ml of normal saline
driven with compressed medical air (placebo). The design
of the Circulaire® nebulizer system incorporates an inflat-
able reservoir bag, which collects nebulized gas during the
exhalation phase so that during the inhalation phase, and
the subject receives both freshly generated nebulized drug
and stored nebulized drug at a sufficient rate. Thus, no
ambient air is entrained into the system, ensuring that
nebulized gas concentrations are maintained throughout
the breathing cycle.
Three S-1226 formulations were tested:
1. S-1226 (4 %): composed of perflubron and 4 % CO2
2. S-1226 (8 %): composed of perflubron and 8 % CO2
3. S-1226 (12 %): composed of perflubron and 12 % CO2
Each S-1226 formulation was administered by inhal-
ation for a period of 2 minutes, with 0 h defined as the
end of nebulization. Subjects were allowed to stop treat-
ment at any time at the appearance of adverse events
(AEs), including intolerable anxiety or panic.
Subjects were confined in the clinical site for 24 h fol-
lowing administration of S-1226 for procedural and
safety measures. Normally, CO2 is eliminated from the
body via exhalation at the same rate at which it is pro-
duced. In addition, perflubron is an extremely stable and
inert compound that is excreted as a vapor during exhal-
ation. Therefore, a 24-h confinement was long enough
to collect and monitor any AEs that might occur.
No food was allowed from at least 10 h before dosing
until at least 2 h after dosing. Controlled meals were
served at appropriate times during the remainder of the
confinement period. Meals were similar in composition
for all cohorts. The evening before dosing, subjects were
asked to drink at least two glasses of water (approxi-
mately 240 ml each). On the morning of dosing, subjects
were asked to drink at least one glass of water (approxi-
mately 240 ml) at least 1 h predose. Starting at 1 h pre-
dose, no fluids were allowed until 1 h postdose. At 1 h
after study treatment, subjects were asked to drink at
least one glass (approximately 240 ml) of water every
4 h over the 12-h period following study treatment.
Thereafter, water was provided ad libitum.
Safety parameters, including laboratory results and
ECG, were assessed by the qualified investigator or dele-
gate. In making the medical assessment, the clinical site
criteria for laboratory and ECG acceptance ranges were
used as suggested guidelines. Scheduled safety measure-
ments were repeated according to the clinical site stand-
ard operating procedures or upon request from a
physician. Any abnormal measurement was evaluated by
a physician and repeated if judged necessary. No phar-
macokinetic assessments of perflubron were performed,
as the dose of perflubron in S-1226 is below the detec-
tion limit of headspace gas chromatography with elec-
tron capture detection, the most sensitive analytical
technique to measure perflubron in the blood and urine.
Primary and secondary outcome measures
Safety and tolerability to S-1226 were evaluated through
the assessment of AEs, vital signs (respiratory rate, blood
pressure, and heart rate), 12-lead ECG, clinical labora-
tory parameters (spirometry), and physical examination,
as detailed in Table 1. Safety and tolerability data were
reported using descriptive statistics.
The data captured for this study allowed for adequate
evaluation of the safety of the subjects after product ad-
ministration. These data (AEs, vital signs, 12-lead ECG,
clinical laboratory parameters, and physical examination)
were reviewed by the qualified investigator throughout
Green et al. Trials  (2016) 17:361 Page 5 of 13
the study and by the safety monitoring committee after
the completion of cohorts 1 and 2. On the basis of the
results of the documented measurements, the safety
monitoring committee determined that all subsequent
dosing could proceed according to the protocol. The
collected measurements provided the qualified investiga-
tor and safety monitoring committee adequate data to
assess the subjects objectively and provide a study con-
clusion. The efficacy of the tested products was not eval-
uated for this study.
Sample size
The sample size of 12 subjects per cohort is a number
commonly used in first-in-human studies, and it was
judged appropriate to achieve the study’s objectives. A
total of 36 subjects were recruited into the study.
Randomization and blinding
The randomization scheme was generated by PMRI. Par-
ticipants were randomly assigned using the randomization
procedures to either the S-1226 or the placebo group
within each cohort. Randomization was carried out by
using a computer-generated random list of numbers pre-
pared and checked by designated personnel with no direct
involvement with the clinical aspects of the trial. The
numbered list was generated separately for each cohort
before administration of the drug, and labels were placed
on the unit dose package.
Both study subjects and the clinical personnel involved
in the collection, monitoring, revision, or evaluation of
AEs, as well as personnel who could have an impact on
the outcome of the study, were blinded with respect to
subject treatment assignment until the clinical phase of
the study was completed (i.e., when investigation and
reporting of all AEs were completed). The study personnel
responsible for subject dosing were not involved in the
collection, monitoring, revision, or evaluation of AEs. Des-
ignated personnel at the clinical site not directly involved
with the clinical aspects of the trial prepared (including
loading the nebulizer) and dispensed the study medication
and were aware of the randomization code. Before admin-
istration of the drug to the participant, the appropriate in-
dividual subject randomization envelope was opened,
which revealed which treatment was to be administered.
Research pharmacists dispensed either the drug or pla-
cebo according to the randomization list.
In the event of an emergency, an envelope for each sub-
ject containing the subject’s treatment assignment was
available from the clinical site personnel involved with the
preparation of the study medication. The qualified investi-
gator or other attending study physician (subinvestigator)
was required to make every effort to contact the sponsor
prior to unblinding a subject’s treatment assignment and
to record the date and reason for the unblinding in the
study source documents.
To avoid compromising blinding of the study, S-1226
and placebo had the same visual appearance, and the
same model of hospital nebulizer was used for adminis-
tration of both compounds. The compressed gas mix-
tures were similarly blinded. The perflubron and
placebo (saline) used in the study were delivered to the
clinical trial facility in different forms. The perflubron
was contained in 3-ml sterile bottles, while the saline
was delivered in ampoules. Apart from the packaging,
both were in liquid form and had the same visual ap-
pearance. Before administration to the participants,
both S-1226 and placebo were repackaged into 51.75 ml
snap-cap amber vials and consecutively numbered for
each participant according to the randomization schedule.
Each participant was assigned an order number and re-
ceived the drugs in the corresponding prepacked bottle.
The same model of hospital nebulizer was used for ad-
ministration of both compounds.
Ethical conduct of the study
Trained personnel obtained written informed consent
from each participant prior to enrolling the participant
in the study. Participants were permitted to withdraw
from the study at any time. This phase I study received
ethical approval from the Optimum Clinical Research
Inc. Institutional Review Board. This study was con-
ducted in accordance with the following:
1. Current Health Canada Therapeutic Products
Directorate guidance documents
2. Good Clinical Practice as established by the
International Conference on Harmonization
3. Basic principles defined in the U.S. Code of Federal
Regulations (21 CFR Part 312)
4. Principles enunciated in the World Medical
Association Declaration of Helsinki (October 2013)
Informed consent
All subjects signed a privacy consent form prior to dis-
closing any personal information and prior to undergo-
ing any medical procedures. Upon study entry, subjects
were given a copy of the current informed consent form
to read and were given the opportunity to ask questions.
When all questions were satisfactorily answered, subjects
were asked to sign the informed consent form prior to
study initiation.
Statistical methods
The primary endpoint of the study was to evaluate the
safety and tolerability of S-1226, composed of perflubron
with ascending doses of CO2 (4 %, 8 %, and 12 % CO2),
administered to healthy subjects over a 2-minute
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nebulization period. The study had no secondary efficacy
endpoints.
Descriptive statistics were presented for demographic pa-
rameters by treatment group and for all other parameters.
Treatment-emergent AEs were summarized descriptively
by treatment for all subjects who were dosed (safety popu-
lation). No inferential statistical analysis of safety data was
planned. Safety and tolerability data were reported using
descriptive statistics.
Results
Participants were recruited in March 2014, and the study
was completed on 17 May 2014. The final report of the
study was completed in September 2014. The study had
three cohorts, with each cohort receiving a different
concentration of CO2 in the S-1226 treatment. Overall,
nine participants were randomly assigned to receive the
placebo (saline), nine to receive S-1226 (4 % CO2), nine
to receive S-1226 (8 % CO2), and nine to receive S-1226
(12 % CO2), as summarized in Fig. 1. The treatment
groups were comparable for most demographic and
baseline characteristics (Table 2).
There was a minor protocol modification in the study.
Spirometry training was scheduled to be performed on
the night of check-in, and the predose spirometry meas-
urement was scheduled to be performed within 1 h prior
to drug administration. After discussions with the spon-
sor and the investigator, owing to tight time constraints,
the predose spirometry test was performed within 2 h
prior to drug administration for cohort 2 and cohort 3.
This modification had no impact on the safety of the
subjects.
One participant in cohort 3 was discontinued from
the study and was not replaced. The participant had
shortness of breath during dosing and was unable to
maintain a tight mouth seal. This participant’s short-
ness of breath was deemed to have a possible relation-
ship to the drug. However, this participant was
included in safety data analyses.
Baseline characteristics
Baseline patient demographic and clinical characteristics
are summarized in Table 2.
Safety
The safety monitoring committee reviewed all relevant
safety data upon completion of the first cohort. All com-
mittee members unanimously agreed to proceed to the
Fig. 1 2010 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Participant enrollment, allocation, and analysis in S-1226 (4 %,
8 %, and 12 % CO2) and placebo treatment groups. PFOB perflubron
Green et al. Trials  (2016) 17:361 Page 7 of 13
next dosing levels of 8 % and 12 % without concern. A
total of 28 AEs were reported throughout the study. All
AEs were adjudged mild in severity. Thirteen subjects
(48.1 %) reported twenty-four AEs after receiving the
test product, and three (33.3 %) subjects reported four
AEs after receiving the placebo product (Table 3).
Three AEs (10.7 %) were reported with an S-1226 dose
of 4 % CO2, one AE (5.0 %) with 8 % CO2, and twenty
AEs (71.4 %) with 12 % CO2. AEs were observed in
system organ classes of cardiac disorders (n = 4); general
disorders and administration site conditions (n = 3); in-
vestigations (n = 6); nervous system disorders (n = 8); re-
spiratory, thoracic, and mediastinal disorders (n = 6); and
vascular disorders (n = 1). The most frequent AE was
somnolence, which was reported by four subjects (two
at 4 % CO2, one at 8 % CO2, and one at 12 % CO2)
(Table 4). Other commonly reported AEs were dyspnea,
dizziness, bradycardia, and feeling hot.
Table 2 Baseline patient demographic and clinical characteristics
Cohort 1 Cohort 2 Cohort 3













Mean ± SD 35 ± 12 35 ± 11 35 ± 10 31 ± 3 33 ± 10 27 ± 11
Median 30 36 32 32 30 23
Range 22–55 23–45 22–51 28–34 21–45 19–39
Height, cm
Mean ± SD 170.2 ± 7.1 166.7 ± 4.2 168.0 ± 10.7 171.3 ± 2.8 166.4 ± 8.8 186.0 ± 6.5
Median 170.7 164.6 164.6 170.5 165.5 183.9
Range 155.7–182.2 164.0–171.5 155.4–184.5 169.0–174.5 153.0–181.4 180.8–193.2
Weight, kg
Mean ± SD 73.5 ± 12.4 69.4 ± 13.7 69.3 ± 13.2 67.4 ± 9.5 65.3 ± 9.1 81.3 ± 12.7
Median 75.3 63.4 65.0 62.2 62.0 75.5
Range 58.4–96.8 59.7–85.1 53.1–94.0 61.6–78.4 51.9–78.0 72.6–95.9
BMI, kg/m2
Mean ± SD 25.3 ± 3.6 24.8 ± 3.6 24.4 ± 2.5 22.9 ± 2.4 23.6 ± 2.5 23.6 ± 4.3
Median 26.5 23.4 24.9 21.8 23.7 22.2
Range 20.0–29.2 22.2–28.9 19.5–28.5 21.2–25.7 19.2–26.4 20.2–28.4
Age group, years, n (%)
< 18 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
18–40 7 (77.8 %) 2 (66.7 %) 7 (77.8 %) 3 (100 %) 6 (66.7 %) 3 (100 %)
41–55 2 (22.2 %) 1 (33.3 %) 2 (22.2 %) 0 (0 %) 3 (33.3 %) 0 (0 %)
Sex, n (%)
Female 2 (22.2 %) 3 (100 %) 5 (55.6 %) 2 (66.7 %) 8 (88.9 %) 0 (0 %)
Male 7 (77.8 %) 0 (0 %) 4 (44.4 %) 1 (33.3 %) 1 (11.1 %) 3 (100 %)
Ethnicity, n (%)
Hispanic or Latino 2 (22.2 %) 1 (33.3 %) 3 (33.3 %) 2 (66.7 %) 4 (44.4 %) 2 (66.7 %)
Not Hispanic or Latino 7 (77.8 %) 2 (66.7 %) 6 (66.7 %) 1 (33.3 %) 5 (55.6 %) 1 (33.3 %)
Race, n (%)
Black 5 (55.6 %) 1 (33.3 %) 4 (44.4 %) 0 (0 %) 3 (33.3 %) 0 (0 %)
Other (multiracial white and black) 0 (0 %) 1 (33.3 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
White 4 (44.4 %) 1 (33.3 %) 5 (55.6 %) 3 (100 %) 6 (66.7 %) 3 (100 %)
Heart rate, beats/minute, mean ± SD 66.2 ± 10.2 71.7 ± 7.5 61.9 ± 5.4 72.7 ± 9.5 72.3 ± 12.0 70.7 ± 7.4
FEV1, L/minute, mean ± SD 3.4 ± 0.7 2.8 ± 0.2 3.5 ± 1.0 3.9 ± 0.4 3.3 ± 0.7 4.9 ± 0.9
Blood pressure, mmHg,a mean ± SD 87.3 ± 8.0 89.7 ± 5.7 85.6 ± 8.0 89.2 ± 9.4 82.8 ± 9.0 87.0 ± 2.4
BMI body mass index, FEV1 forced expiratory volume in 1 second
aBlood pressure values in participants were expressed as mean arterial pressures
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Treatment and placebo comparison
The number of AEs reported after administration of S-
1226 (4 % CO2) (n = 3), S-1226 (8 % CO2) (n = 1), and
placebo (n = 4) appeared to be similar, while subjects
who received S-1226 (12 % CO2) reported a total of 20
AEs (Table 3). All nine subjects (100 %) who received S-
1226 (12 % CO2) reported at least one AE. Of the 20
(71.4 %) reported AEs, 6 were considered possibly re-
lated to the drug, while 3 AEs were remotely related to
S-1226 (Table 3, Fig. 2). All 20 AEs were adjudged mild in
severity and were spread across several system organ classes
and preferred term groups (Table 4). Therefore, there was
not one AE that was prominently experienced in this study.
Clinical review of the laboratory, ECG, vital sign, and phys-
ical examination data did not indicate any safety concerns
of the investigator or safety monitoring committee.
Discussion
The goal of this study was to evaluate the safety and tol-
erability of S-1226 at ascending doses of carbon dioxide
(4 %, 8 %, and 12 % CO2) in healthy subjects. Twenty-
eight AEs were observed in total, with the majority oc-
curring at the highest dose (12 % CO2) of S-1226. The
number of AEs reported after administration of S-1226
(4 % CO2), S-1226 (8 % CO2), and placebo appeared to
be similar, showing that S-1226 was safe and well toler-
ated at these concentrations. At the highest dose of
S-1226 (12 % CO2), 20 AEs were reported, suggesting
that the risk of an AE increases as the dose of CO2 is
increased. All AEs were mild in severity and were revers-
ible within minutes to hours of the treatment. S-1226, a
formulation of CO2-enriched ambient air delivered in
nebulized perflubron, appeared safe and well tolerated at
all three CO2 levels (4 %, 8 %, and 12 %) when adminis-
tered to healthy volunteers.
In total, of the 24 AEs that occurred with the admin-
istration of S-1226, 5 were considered remotely related
and 7 were considered possibly related to S-1226, as
adjudged by the safety monitoring committee. These
AEs are likely attributable to the known effects of CO2
inhalation and not perflubron, as the amount of perflu-
bron was the same for each cohort while the number of
AEs increased with increasing dose of CO2. Moreover,
most of these AEs, including somnolence, bradycardia,
dizziness, feeling hot, headache, cough, and dyspnea are
well-known side effects of CO2 inhalation, and the par-
ticipants in the study were made aware of these risks
while their informed consent was being obtained [15, 30].
In published clinical studies of CO2 administered at con-
centrations ranging from 2 % to 14 % over 2.5 minutes to
90 minutes, observed side effects, including neurological
symptoms, were mostly mild but could become severe
with prolonged administration of over 10 minutes of ap-
proximately 8 % CO2 or more. Overall, AEs become ap-
parent with inhalation of >5 % CO2 for 4–35 minutes
[14, 31, 32]. Symptoms most commonly reported were
dyspnea, headaches, sweating, and dizziness. Alterations
in mental state (e.g., restlessness, confusion) and feeling
faint occurred more commonly at doses ≥10 % CO2. Loss
of consciousness occurred with longer administration
times (>8 minutes where reported) and at CO2 doses
>10 % CO2 [14, 15, 33]. These effects are dose-dependent
Table 3 Adverse events by severity, relationship to drug, and action taken
S-1226 (4 % CO2) (n = 9) S-1226 (8 % CO2) (n = 9) S-1226 (12 % CO2) (n = 9) Placebo (n = 9) Total (n = 36)
Severity
Mild 3 1 20 4 28
Moderate 0 0 0 0 0
Severe 0 0 0 0 0
Relationship to drug
Probable 0 0 0 0 0
Possible 1 0 6 0 7
Remote 1 1 3 1 6
Unrelated 1 0 11 3 15
Action taken
Dose increased 0 0 0 0 0
Dose not changed 3 1 18 2 24
Dose reduced 0 0 0 0 0
Drug interrupted 0 0 1 0 1
Drug withdrawn 0 0 0 0 0
Not applicable 0 0 1 0 3
Unknown 0 0 0 0 0
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and reversible, returning to normal soon after treatment
cessation. CO2 levels are highly regulated, leading to a
relatively rapid resolution of effects observed after inhal-
ation of concentrations greater than normally occur in ar-
terial blood and alveoli. In this study, CO2 concentrations
of 4 %, 8 %, and 12 % were delivered for 2 minutes to re-
duce the risk of symptoms associated with higher concen-
trations and extended delivery of CO2.
Furthermore, inhaled 6 % CO2 has been shown to re-
lieve airway obstruction with no reported AEs in pa-
tients with asthma who experience exercise-induced
bronchospasm [13]. On the basis of this finding and
prior clinical research with inhaled CO2 and perflubron,
including the presence at least 5 % CO2 dissolved in per-
flubron within the lungs of patients treated with perflu-
bron as bronchial lavage or a partial liquid ventilation
agent, S-1226 (4 % CO2) administered for 2 minutes was
selected as a safe starting dose. Following a safety evalu-
ation of this concentration, 8 % CO2 and 12 % CO2 were
subsequently delivered to subjects, with previous
preclinical animal studies supporting that they would be
safe and effective to administer for 2 minutes. This range
of doses of CO2 was chosen on the basis of safety studies
in humans indicating that 12 % is the upper limit and ef-
ficacy studies in animal models of asthma.
On the basis of previous clinical research, the AEs in
this study are likely accounted for as known side effects
of CO2 inhalation and not related to perflubron. The
toxicology profile of perflubron is well researched, and it
is considered safe to use. Perflubron is biologically inert
and is not metabolized [21]. It is a synthetic surfactant
that has been administered to humans in high doses or-
ally, intravenously, and by liquid instillation directly into
the lungs. The majority of perflubron instilled into the
lungs is eliminated from the body through respiration,
as perflubron readily evaporates from surface tissues and
is exhaled. In addition, very small proportions of the per-
flubron instilled in the respiratory tract partitions into
blood [34]. It has been shown to improve lung compli-
ance and gas exchange in pulmonary applications, and it
Table 4 Incidence of adverse events by system organ class and preferred terms
System organ class Preferred term S-1226 (4 % CO2)
(n = 9)
S-1226 (8 % CO2)
(n = 9)






Subjects with one or more
adverse events
3 (33.3 %) 1 (11.1 %) 9 (100 %) 3 (33.3 %) 16 (44.4 %)
Subjects with no adverse
events
6 (66.7 %) 8 (88.9 %) 0 (0 %) 6 (66.7 %) 20 (55.6 %)
Cardiac disorders Bradycardia 1 (11.1 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 2 (5.6 %)
Palpitations 0 (0 %) 0 (0 %) 0 (0 %) 1 (11.1 %) 1 (2.8 %)
Hypertension 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Subtotal 1 (11.1 %) 0 (0 %) 2 (22.2 %) 1 (11.1 %) 4 (11.1 %)
General disorders and
administration site conditions
Feeling hot 0 (0 %) 0 (0 %) 3 (33.3 %) 0 (0 %) 3 (8.3 %)
Subtotal 0 (0 %) 0 (0 %) 3 (33.3 %) 0 (0 %) 3 (8.3 %)
Investigations Neutrophil count decreased 0 (0 %) 0 (0 %) 2 (22.2 %) 1 (11.1 %) 3 (8.3 %)
White blood cell count decreased 0 (0 %) 0 (0 %) 0 (0 %) 1 (11.1 %) 1 (2.8 %)
Electrocardiogram QT prolongation 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Electrocardiogram PR prolongation 0 (0 %) 0 (0 %) 0 (0 %) 1 (11.1 %) 1 (2.8 %)
Subtotal 0 (0 %) 0 (0 %) 3 (33.3 %) 3 (33.3 %) 6 (16.7 %)
Nervous system disorders Dizziness 0 (0 %) 0 (0 %) 3 (33.3 %) 0 (0 %) 3 (8.3 %)
Headache 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Somnolence 2 (22.2 %) 1 (11.1 %) 1 (11.1 %) 0 (0 %) 4 (11.1 %)
Subtotal 2 (22.2 %) 1 (11.1 %) 5 (55.6 %) 0 (0 %) 8 (22.2 %)
Respiratory, thoracic, and
mediastinal disorders
Cough 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Dyspnea 0 (0 %) 0 (0 %) 3 (33.3 %) 0 (0 %) 3 (8.3 %)
Respiratory tract irritation 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Throat irritation 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Subtotal 0 (0 %) 0 (0 %) 6 (66.7 %) 0 (0 %) 6 (16.7 %)
Vascular disorders Tachycardia 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
Subtotal 0 (0 %) 0 (0 %) 1 (11.1 %) 0 (0 %) 1 (2.8 %)
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has been marketed as a gastrointestinal imaging agent in
the United States (Imagent® GI; Alliance Pharmaceutical
Corp., San Diego, CA, USA) using a dose of 9 ml of per-
flubron per kilogram of body weight and as a bronchial
lavage solution in Canada (Liquivent®, previously called
Perflubronc®-B; OriGen Biomedical, Austin, TX, USA),
showing it is safe to use and well tolerated by humans [35].
Both components of S-1226, perflubron and CO2, have
undergone extensive clinical testing as separate agents,
and their safety profiles are well known. CO2 and perflu-
bron do not chemically interact. Due to the natural elim-
ination of CO2 by respiration, clinical liquid ventilation
studies with large volumes of perflubron, as well as clinical
use of perflubron as a licensed bronchial lavage solution
(Liquivent®), have involved levels of approximately 5 % or
greater CO2 dissolved in perflubron within the lungs.
S-1226 is intended for clinical use as a single-dose
treatment for acute asthma exacerbations. If multiple
treatments are indicated in future studies, additional
safety studies will be required. S-1226 is to be used
within hospital emergency rooms, where rapid treatment
administration and immediate relief of acute airway ob-
struction are vital. S-1226 has a unique mechanism of
action independent of the β-adrenergic and cholinergic
mechanism of conventional therapies and offers a novel
treatment in cases where these other therapies have
proven ineffective. Moreover, S-1226 dilates airways
within seconds and can be combined with traditional
medications and oxygen therapy to provide more effect-
ive and sustained relief following an exacerbation. In the
future, if S-1226 is shown to be effective in humans, it
may be possible to develop a rescue device similar to an
EpiPen® (Mylan) for patients with asthma to be used fol-
lowing an acute asthma exacerbation to rapidly dilate
the airways. S-1226 may also serve as a platform tech-
nology to enhance delivery of other drugs to the lung.
On the basis of this phase I trial demonstrating the
safety and tolerability of S-1226 in humans, as well as pre-
clinical studies that have shown the efficacy of S-1226 in
rapidly dilating the airways in sheep and rat models of
Fig. 2 Flow diagram of related adverse events (AEs) in S-1226 (4 %, 8 %, and 12 % CO2) and placebo treatment groups based on their relationship
to the drug (possibly or remotely). ECG electrocardiogram, WBC white blood cell
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asthma, a phase II trial designed to determine the efficacy
of S-1226 in patients with mild atopic asthma has been
developed and is currently ongoing. In this single-dose,
placebo-controlled crossover trial, a 8 % CO2 dose will be
used. This dose was chosen because it produced the few-
est AEs in the phase I trial.
Conclusions
This phase I study shows that S-1226 is safe and well
tolerated when administered to healthy humans at 4 %,
8 %, and 12 % CO2 nebulized in 3 ml of perflubron. All
AEs associated with S-1226 were mild and reversible
and were likely due to the known side effects of CO2 in-
halation. S-1226 has the potential to be a rescue therapy
for acute asthma exacerbations.
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